Search | Page 20 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Pediatric MDS

    ... because there are certain subtypes of MDS, for example, refractory anemia with ringed sideroblasts (RARS), that don’t ...

    Interview last updated 10/24/2012 - 1:31pm.

  2. Treating Higher-Risk Myelodysplastic Syndromes

    ... higher-risk. For example, the two categories of Refractory Anemia with Excess Blasts (RAEB-1 and RAEB-2) ...

    Interview last updated 05/18/2012 - 1:55pm.

  3. North American Pediatric Aplastic Anemia Consortium Symposium

    ... in the particularly difficult distinction of SAA from refractory cytopenia of childhood (RCC), a subtype of ...

    Page last updated 10/31/2013 - 4:06pm.

  4. What MDS Patients Should Know About Clinical Trials

    ... therapies that didn’t’ work for them? We call this refractory MDS, where there was no improvement after 4 or 6 months, or ...

    Interview last updated 11/13/2015 - 11:12am.

  5. Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

    ... 2 times the normal value Absence of encephalopathy, refractory or infected ascites , esophageal varicose of grade > 1 at ...

    Clinical Trial last updated 04/29/2016 - 9:59am.

  6. Clinical Trials Report for January 2015

    ... pharmacokinetics of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess ...

    Page last updated 12/30/2014 - 10:45am.

  7. Clinical Trials Report for January 2016

    ... risk myelodysplastic syndrome (MDS) that is relapsed/ refractory to erythropoiesis-stimulating agent (ESA) treatment. This ...

    Page last updated 01/07/2016 - 10:57am.

  8. Clinical Trials Report for March 2015

    ... of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess ... cohorts of three or more patients with RR-AML or HMA-refractory MDS will be treated at escalating doses until a maximum tolerated ...

    Page last updated 03/02/2015 - 10:06am.

  9. Clinical Trials Report for April 2015

    ... pharmacokinetics of TEN-010 in patients with relapsed/ refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess ...

    Page last updated 03/30/2015 - 11:40am.

  10. Clinical Trials Report for February 2015

    ... Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia ...

    Page last updated 01/29/2015 - 10:10am.